Zohar Sachs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2101077/publications.pdf

Version: 2024-02-01

30 papers	351 citations	933447 10 h-index	839539 18 g-index
30 all docs	30 docs citations	30 times ranked	732 citing authors

#	Article	IF	Citations
1	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer Journal, 2021, 11, 18.	6.2	8
2	High risk of relapse with intermediate dose cytarabine for consolidation in young favourableâ€risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. British Journal of Haematology, 2021, 194, 140-144.	2.5	5
3	Primary Cardiac Lymphoma: Three Case Reports and a Review of the Literature. Open Journal of Blood Diseases, 2021, 11, 120-132.	0.1	6
4	Proteasome Inhibition Attenuates Self-Renewal in Human Acute Myeloid Leukemia By Targeting NF-Kappa B in Leukemia Stem Cells. Blood, 2021, 138, 3347-3347.	1.4	3
5	Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia. Cancer Research, 2020, 80, 458-470.	0.9	46
6	Prognostic factors for clinical outcomes of patients with central nervous system leukemia. Hematology/ Oncology and Stem Cell Therapy, 2020, 14, 240-245.	0.9	2
7	Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome. Leukemia Research, 2020, 95, 106404.	0.8	1
8	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. Blood, 2020, 136, 21-22.	1.4	0
9	JAK/STAT Inhibition Targets TP53 altered Primary Human Acute Myeloid Leukemia Stem Cells. Blood, 2020, 136, 27-28.	1.4	2
10	Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival. Journal of Proteome Research, 2019, 18, 1842-1856.	3.7	14
11	Sarcoid-like Histiocytic Proliferations in Patients With Lymphoma Can Be FDG-avid Concerning for Refractory or Recurrent Disease. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e597-e601.	0.4	3
12	High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3. Blood, 2019, 134, 3432-3432.	1.4	2
13	Novel single-cell technologies in acute myeloid leukemia research. Translational Research, 2017, 189, 123-135.	5.0	9
14	Buccal epithelial cells display somatic, bone marrowâ€“derived CALR mutation. Blood Advances, 2017, 1, 2302-2306.	5.2	2
15	Human Melanoma-Derived Extracellular Vesicles Regulate Dendritic Cell Maturation. Frontiers in Immunology, 2017, 8, 358.	4.8	54
16	Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. Haematologica, 2016, 101, 1190-1199.	3.5	14
17	mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Molecular Cell, 2016, 61, 625-639.	9.7	59
18	Double- and triple-hit lymphomas can present with features suggestive of immaturity, including TdT expression, and create diagnostic challenges. Leukemia and Lymphoma, 2016, 57, 2626-2635.	1.3	34

#	Article	IF	Citations
19	Immunoproteasome Inhibition to Target AML with Activated RAS Pathways. Blood, 2016, 128, 577-577.	1.4	0
20	Germline Calr Mutation and Thrombocytosis Presenting with Concomitant BCR-ABL1+ CML. Blood, 2016, 128, 5494-5494.	1.4	1
21	86: CALR Mutation Thrombocytosis Following Imatinib Treatment for BCR-ABL1+ Chronic Myelogenous Leukemia: A Case of Concomitant Genetic Alterations in an Overlap Myeloproliferative Neoplasm. American Journal of Clinical Pathology, 2015, 143, A049-A049.	0.7	0
22	Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2015, 21, 866-872.	2.0	19
23	Synthesis and antileukemic activities of C1â€“C10-modified parthenolide analogues. Bioorganic and Medicinal Chemistry, 2015, 23, 4737-4745.	3.0	23
24	Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma. Journal of Cancer, 2014, 5, 720-727.	2.5	20
25	NRAS G12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. Blood, 2014, 124, 3274-3283.	1.4	24
26	Ras-Pathway Inhibition With Targeted Therapies Abrogates Self-Renewal In Acute Myelogenous Leukemia. Blood, 2013, 122, 819-819.	1.4	0
27	Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9-Specified Gene Expression Signature. Blood, 2012, 120, 5116-5116.	1.4	0
28	Are IPSS-R and IPSS Cytogenetic Risk Stratification Informative At the Time of Allogeneic Hematopoietic Cell Transplantation?. Blood, 2012, 120, 1400-1400.	1.4	0
29	Delineating Critical Effectors of Remission Induction in a Mouse Model of AML. Blood, 2011, 118, 5232-5232.	1.4	0
30	Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations. Blood, 2010, 116, 3160-3160.	1.4	0